Chargement en cours...
Biosimilars in the management of neutropenia: focus on filgrastim
Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to...
Enregistré dans:
| Format: | Article |
|---|---|
| Langue: | en |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762467/ https://ncbi.nlm.nih.gov/pubmed/26937170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S73580 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|